Investigational drug for metastatic pancreatic ductal adenocarcinoma

Trial ID:
IRB-25-8686
Darren Sigal, M.D.

Inclusion Criteria

Patients must:

  • Be 18 years of age or older
    Have histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma
    Have homozygous MTAP deletion or MTAP loss detected in tumor tissue

Exclusion Criteria

Patients must not:

  • Have received any systemic anticancer treatments in the metastatic setting
    Be pregnant, breastfeeding, or planning to conceive during the study
    Have had a prior organ allograft
    Have uncontrolled/symptomatic or significant cardiovascular conditions within 6 months prior to study treatment

Additional Info

This is a blinded study which means the participant, study team, and physician will not know if the participant will receive BMS-986504 or placebo.

All treatments and physician visits will take place at Scripps Clinic Torrey Pines.

For more information, search NCT07076121 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org